AB0681 HISTORY OF ABORTION AND MULTIPARITY IN SYSTEMIC AUTOIMMUNE DISEASES: RESULTS FROM A MULTIDISCIPLINARY PREGNANCY CLINIC (GYNECOLOGY, RHEUMATOLOGY AND NEPHROLOGY)

Background Pre-conception counselling and risk stratification performed in a multidisciplinary clinical setting with rheumatologists, obstetricians nephrologists may improve pregnancy outcomes systemic autoimmune disease (SAD). Objectives To compare clinical, obstetrical comorbidities patients SAD history of loss without loss. Methods A retrospective cohort study was conducted. total 41 SADs that attended the preconception outpatient clinic were included. Variables related to SADs, obstetric collected. Description sample comparison groups carried out. Shapiro-Wilk test used normality. Results The description comorbidities, are summarized Table 1. 18 (46%) had Fewer loss, 38.5% fit for conception compared 54.3% Deferment advised Patients significantly higher anti-DNAds, antiphospholipid positivity longer time since last flare.There no significant difference adverse outcomes, activity or treatment. Interestingly, distribution profile different between both groups: there more moderate high Conclusion present delay plan new pregnancy, anti-DNA positivity. No worse observed. previous abortion (n=13) abortions (n=28) P value Sociodemographic data Age at visit (year) 36.8±4.61 34.4±3.93 0.43 diagnosis 28.31±2.48 28.617±1.35 0.9 Diagnosis-1 st (years) 8±6.71 6.93±5.5 0.58 Last flare-1 (months) 47±39.45 27±38.59 0.049 Immunological Anti-DNAds 61.17±52.46 42.62±52.46 0.043 LA, n (%) 11 (84.6) 5 (17.9) 0.004 Anti-cardiolipin, 9 (69.2) 0.003 Ro52, 3 (23.1) 4 (14.3) 0.49 Ro60, 1 (7.7) 0.55 Diagnosis, (%): -SLE 6 (46.2) 13 (46.4) 0.99 -APS (7.5) (3.57) -Autoinflammatory 0 (10.71) 0.39 -Other (39.3) 0.68 Before Treatment, (% ) -c/tsDMARD (30.8) 7 (25) -HCQ (7.9) - bDMARDs 2 (15.4) (32) GC (n, % (53.9) 14 (49.9) 0.82 CYC (10.7) 0.67 After 0.24 Complications (n,%): -Medical -Obstetrical Fertility assistance 0.73 -Assisted Non-assisted (100) (8.3) (91.7) Abortion (7.69) 0.44 Disclosure Interests None declared